e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Potential of regulatory T-cell-based therapies in the management of severe COVID-19
Emmanuel Stephen-Victor, Mrinmoy Das, Anupama Karnam, Bruno Pitard, Jean-François Gautier, Jagadeesh Bayry
Source:
Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020
Journal Issue:
September
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Emmanuel Stephen-Victor, Mrinmoy Das, Anupama Karnam, Bruno Pitard, Jean-François Gautier, Jagadeesh Bayry. Potential of regulatory T-cell-based therapies in the management of severe COVID-19. Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Recommendations of new therapies for severe asthma and the future
Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma
Year: 2013
Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies
Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy
Year: 2017
Clinical implications and novel therapies
Source: International Congress 2018 – Accelerated ageing in lungs
Year: 2018
Clinical implications and opportunities for new drug therapies
Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications
Year: 2008
Recommended new therapies for severe asthma and the future
Source: International Congress 2014 – PG05 Severe asthma – highlights from the ERS/ATS workshop
Year: 2014
Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19
Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020
Year: 2020
Novel targets and emerging therapies in MPM
Source: ERS Skills course: Multi-disciplinary care in thoracic oncology
Year: 2019
Current and future preventive and treatment strategies in CLAD
Source: International Congress 2015 – When chronic inflammation drives fibrosis: a lesson from lung transplantation
Year: 2015
A pragmatic guide to choosing biologic therapies in severe asthma
Source: Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021
Year: 2021
COPD mechanisms: novel aspects and implications for new therapies
Source: ERS Live 2007
Year: 2007
Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021
Year: 2022
Alternative immunosuppressive strategies
Source: ERS Course 2016
Year: 2016
COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness
Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020
Year: 2020
Genes, mechanisms and new therapies for asthma
Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Year: 2010
Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept